单针接种疫苗
single dose vaccine

2月25日，由中国工程院院士、军事科学院军事医学研究院研究员陈薇领衔的团队研发的我国重组新冠病毒疫苗（腺病毒载体新冠疫苗），获国家药品监督管理局附条件批准（conditional market approval）上市注册申请。

The vaccine, called Ad5-nCoV, has an efficacy rate of 65.7 percent at preventing symptomatic cases and is 90.9 percent effective in preventing severe disease with a single injection, according to interim analysis of late-stage human trials released in February.